Revenue Breakdown
Composition ()
No data
Revenue Streams
Sarepta Therapeutics Inc (SRPT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is collaboration and other, accounting for 54.8% of total sales, equivalent to $400.29M. Other significant revenue streams include PMO Products and ELEVIDYS. Understanding this composition is critical for investors evaluating how SRPT navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Sarepta Therapeutics Inc maintains a gross margin of 85.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 49.05%, while the net margin is 45.29%. These profitability ratios, combined with a Return on Equity (ROE) of 4.91%, provide a clear picture of how effectively SRPT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SRPT competes directly with industry leaders such as PAHC and DFTX. With a market capitalization of $2.11B, it holds a significant position in the sector. When comparing efficiency, SRPT's gross margin of 85.02% stands against PAHC's 32.77% and DFTX's N/A. Such benchmarking helps identify whether Sarepta Therapeutics Inc is trading at a premium or discount relative to its financial performance.
